Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 8/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.48 |
| ▸ | MLNR | O43193 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL7095796 | 0.85 | ADRB3 (0.61) | ADRB3ADRB1 | |
| SCHEMBL7094544 | 0.83 | ADRB3 (0.49) | GNAI3GNAI1GNAO1MLNRCNR2 | |
| Formic Acid SCHEMBL7092211 | 0.82 | ADRB3 (0.54) | MLNRADRB3ADRB1MAPT | |
| Formic Acid SCHEMBL7095073 | 0.81 | TPSAB1 (0.47) | MLNRADRB3ADRB1MAPT | |
| Formic Acid SCHEMBL7096122 | 0.81 | ADRB3 (0.55) | MLNRADRB3ADRB1MAPT | |
| Formic Acid SCHEMBL7571773 | 0.81 | ADRB3 (0.56) | GNAI3GNAI1GNAO1ADRB3ADRB1 | |
| SCHEMBL7095127 | 0.81 | ADRB3 (0.62) | ADRB3ADRB1 | |
| Formic Acid SCHEMBL7096335 | 0.81 | ADRB3 (0.57) | MLNRADRB3ADRB1MAPT | |
| Formic Acid SCHEMBL7570814 | 0.79 | GHSR (0.54) | ADRB3ADRB1 | |
| Formic Acid SCHEMBL7094336 | 0.78 | ADRB3 (0.58) | MLNRADRB3ADRB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | GNAI3 187/4885GNAI1 295/4885GNAO1 182/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | GNAI3 161/4885GNAI1 199/4885GNAO1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.